Metoprolol tartrate and Rapaflo drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Metoprolol tartrate and Rapaflo. Common interactions include cough among females and fatigue among males.

The phase IV clinical study analyzes what interactions people who take Metoprolol tartrate and Rapaflo have. It is created by eHealthMe based on reports of 74 people who take Metoprolol tartrate and Rapaflo from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Aug, 17, 2022

74 people who take Metoprolol tartrate and Rapaflo together, and have interactions are studied.


What is Metoprolol tartrate?

Metoprolol tartrate has active ingredients of metoprolol tartrate. It is often used in high blood pressure. eHealthMe is studying from 76,736 Metoprolol tartrate users for its effectiveness, alternative drugs and more.

What is Rapaflo?

Rapaflo has active ingredients of silodosin. It is often used in prostate examination abnormal. eHealthMe is studying from 3,508 Rapaflo users for its effectiveness, alternative drugs and more.

Number of Metoprolol tartrate and Rapaflo reports submitted per year:

Metoprolol tartrate and Rapaflo drug interactions.

Common Metoprolol Tartrate and Rapaflo drug interactions by gender *:

female:

  1. Cough
  2. Dysgeusia
  3. Fibromyalgia
  4. Psoriasis
  5. Stress

male:

  1. Fatigue
  2. Insomnia
  3. Decreased appetite
  4. Somnolence
  5. Arthralgia
  6. Death
  7. Depression
  8. Fall
  9. Stent placement
  10. Constipation

Common Metoprolol Tartrate and Rapaflo drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Aneurysm
  2. Angina pectoris
  3. Cardiac disorder
  4. Diarrhoea
  5. Vomiting

50-59:

  1. Acute myocardial infarction
  2. Death
  3. Pulmonary embolism

60+:

  1. Fatigue
  2. Asthenia
  3. Arthralgia
  4. Back pain
  5. Bladder neoplasm
  6. Blood creatinine increased
  7. Bronchitis
  8. Cataract
  9. Death
  10. Depression

Common conditions people have *:

  1. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 19 people, 25.68%
  2. Cataplexy (loss of muscle tone accompanied by full conscious awareness): 19 people, 25.68%
  3. Prostate Cancer: 10 people, 13.51%
  4. Pain: 8 people, 10.81%
  5. Renal Cell Carcinoma (a kidney cancer): 5 people, 6.76%
  6. Drowsiness: 5 people, 6.76%
  7. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 4 people, 5.41%

* Approximation only. Some reports may have incomplete information.

Do you take Metoprolol tartrate and Rapaflo?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Metoprolol tartrate and Rapaflo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Metoprolol tartrate interactions:

Browse all interactions between Metoprolol tartrate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Rapaflo interactions:

Browse all interactions between Rapaflo and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on metoprolol tartrate and silodosin (the active ingredients of Metoprolol tartrate and Rapaflo, respectively), and Metoprolol tartrate and Rapaflo (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Metoprolol tartrate and Rapaflo.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: